Comparative Modeling for the Prevention and Control of Uterine Cancer

子宫癌预防和控制的比较模型

基本信息

  • 批准号:
    10331235
  • 负责人:
  • 金额:
    $ 94.79万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2021
  • 资助国家:
    美国
  • 起止时间:
    2021-09-17 至 2026-08-31
  • 项目状态:
    未结题

项目摘要

Uterine cancer is the 4th most common cancer in women and the 7th most frequent cause of cancer-related death. The death rate from uterine cancer is rising faster than for any other tumor. Importantly, uterine cancer is associated with a profound racial disparity. Compared to white women, black women are significantly more likely to die from uterine cancer and this disparity is increasing. The overarching goal of this proposal is to inform cancer control and prevention strategies to reduce the incidence and mortality uterine cancer by improving the prevention, screening, and treatment of the disease. We will accomplish this goal through a collaborative modeling consortium in which three groups develop natural history models of uterine cancer. These models will incorporate known risk factors for uterine cancer and population level changes in the prevalence of these risk factors over time. The models will include pathways for both favorable prognosis (type I) uterine cancer as well as more aggressive (type II) neoplasms. Once developed and validated, we will perform comparative modeling to examine issues of importance to clinicians and policymakers. First, we will examine currently available and emerging strategies for screening and prevention of uterine cancer in women. Second, we will examine the harms, benefits, and cost- effectiveness of treatment strategies for uterine cancer including adjuvant therapy, treatment of metastatic disease, and treatment of recurrent disease including immunotherapy. Third, we will estimate how changing epidemiologic factors and social determinants of health influence racial disparities for uterine cancer. Fourth, we will explore the impact of the rising rate of obesity on incidence and mortality of uterine cancer and develop novel, web-based tools to determine how state-level obesity control activities influence incidence and mortality. Finally, we will explore how the declining hysterectomy rate and changing patterns of care for gynecologic diseases influence uterine cancer incidence and mortality. At the completion of this work, these data will be widely disseminated to patients, providers, and policy makers and have the potential to significantly impact the clinical care of women with uterine cancer and to guide cancer control strategies. Further, these models will serve as an invaluable resource for the uterine cancer community as new clinical questions and challenges emerge.
子宫癌是女性中第四大最常见的癌症,也是第七大最常见的癌症相关原因

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Nina A. Bickell其他文献

P099 Helpful and Challenging Aspects of Family Member Involvement in Goals of Care Conversations
  • DOI:
    10.1016/j.jpainsymman.2016.10.185
  • 发表时间:
    2016-12-01
  • 期刊:
  • 影响因子:
  • 作者:
    Dena Schulman-Green;Jenny L. Lin;Cardinale B. Smith;Shelli L. Feder;Nina A. Bickell
  • 通讯作者:
    Nina A. Bickell
P107 Patient and Physician Views About Family Involvement in Goals of Care Conversations
  • DOI:
    10.1016/j.jpainsymman.2016.10.192
  • 发表时间:
    2016-12-01
  • 期刊:
  • 影响因子:
  • 作者:
    Jenny J. Lin;Cardinale B. Smith;Shelli Feder;Nina A. Bickell;Dena Schulman-Green
  • 通讯作者:
    Dena Schulman-Green

Nina A. Bickell的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Nina A. Bickell', 18)}}的其他基金

DiSRUPT: Dismantling Structural Racism Underlying the Organization of Ambulatory PracTices: an observational study of clinical desegregation
DiSRUPT:消除门诊实践组织中的结构性种族主义:临床废除种族隔离的观察性研究
  • 批准号:
    10474861
  • 财政年份:
    2022
  • 资助金额:
    $ 94.79万
  • 项目类别:
DiSRUPT: Dismantling Structural Racism Underlying the Organization of Ambulatory PracTices: an observational study of clinical desegregation
DiSRUPT:消除门诊实践组织中的结构性种族主义:临床废除种族隔离的观察性研究
  • 批准号:
    10650244
  • 财政年份:
    2022
  • 资助金额:
    $ 94.79万
  • 项目类别:
Comparative Modeling for the Prevention and Control of Uterine Cancer
子宫癌预防和控制的比较模型
  • 批准号:
    10704680
  • 财政年份:
    2021
  • 资助金额:
    $ 94.79万
  • 项目类别:
Comparative Modeling for the Prevention and Control of Uterine Cancer
子宫癌预防和控制的比较模型
  • 批准号:
    10489814
  • 财政年份:
    2021
  • 资助金额:
    $ 94.79万
  • 项目类别:
Community Outreach and Engagement
社区外展和参与
  • 批准号:
    10674514
  • 财政年份:
    2015
  • 资助金额:
    $ 94.79万
  • 项目类别:
Community Outreach and Engagement
社区外展和参与
  • 批准号:
    10454174
  • 财政年份:
    2015
  • 资助金额:
    $ 94.79万
  • 项目类别:
Community Outreach and Engagement
社区外展和参与
  • 批准号:
    10022666
  • 财政年份:
    2015
  • 资助金额:
    $ 94.79万
  • 项目类别:
Insulin Resistance and Breast Cancer Prognosis in Black & White Women
黑人的胰岛素抵抗和乳腺癌预后
  • 批准号:
    8720255
  • 财政年份:
    2012
  • 资助金额:
    $ 94.79万
  • 项目类别:
Insulin Resistance and Breast Cancer Prognosis in Black & White Women
黑人的胰岛素抵抗和乳腺癌预后
  • 批准号:
    9294967
  • 财政年份:
    2012
  • 资助金额:
    $ 94.79万
  • 项目类别:
Insulin Resistance and Breast Cancer Prognosis in Black & White Women
黑人的胰岛素抵抗和乳腺癌预后
  • 批准号:
    8396307
  • 财政年份:
    2012
  • 资助金额:
    $ 94.79万
  • 项目类别:

相似海外基金

Countering sympathetic vasoconstriction during skeletal muscle exercise as an adjuvant therapy for DMD
骨骼肌运动期间对抗交感血管收缩作为 DMD 的辅助治疗
  • 批准号:
    10735090
  • 财政年份:
    2023
  • 资助金额:
    $ 94.79万
  • 项目类别:
The ESCAPE clinical trial of circulating tumor DNA to guide adjuvant therapy in chemo-resistant triple negative breast cancer
循环肿瘤 DNA 指导化疗耐药三阴性乳腺癌辅助治疗的 ESCAPE 临床试验
  • 批准号:
    494901
  • 财政年份:
    2023
  • 资助金额:
    $ 94.79万
  • 项目类别:
    Operating Grants
A Type I Hybrid Effectiveness-Implementation Trial to Evaluate a Navigation-Based Multilevel Intervention to Decrease Delays Starting Adjuvant Therapy Among Patients with Head and Neck Cancer
一项 I 型混合有效性实施试验,用于评估基于导航的多级干预措施,以减少头颈癌患者开始辅助治疗的延迟
  • 批准号:
    10714537
  • 财政年份:
    2023
  • 资助金额:
    $ 94.79万
  • 项目类别:
Multi-modal machine learning to guide adjuvant therapy in surgically resectable colorectal cancer
多模式机器学习指导可手术切除结直肠癌的辅助治疗
  • 批准号:
    10588103
  • 财政年份:
    2023
  • 资助金额:
    $ 94.79万
  • 项目类别:
Efficacy of ethanol adjuvant therapy after resection of malignant soft tissue tumors
恶性软组织肿瘤切除术后乙醇辅助治疗的疗效
  • 批准号:
    22K09407
  • 财政年份:
    2022
  • 资助金额:
    $ 94.79万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Identification of immune response cells and development of novel adjuvant therapy for sublingual immunotherapy
免疫应答细胞的鉴定和舌下免疫治疗新型辅助疗法的开发
  • 批准号:
    21KK0287
  • 财政年份:
    2022
  • 资助金额:
    $ 94.79万
  • 项目类别:
    Fund for the Promotion of Joint International Research (Fostering Joint International Research (A))
Pursuing molecular biomarkers to guide adjuvant therapy for HPV+ head and neck cancers after transoral robotic surgery
寻找分子生物标志物来指导经口机器人手术后 HPV 头颈癌的辅助治疗
  • 批准号:
    10357120
  • 财政年份:
    2022
  • 资助金额:
    $ 94.79万
  • 项目类别:
Biomarker research using two prospective studies on preoperative and postoperative adjuvant therapy for pancreatic cancer
使用两项关于胰腺癌术前和术后辅助治疗的前瞻性研究进行生物标志物研究
  • 批准号:
    21K08700
  • 财政年份:
    2021
  • 资助金额:
    $ 94.79万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Personalized Resistant Starch as an Adjuvant Therapy for Pediatric Inflammatory Bowel Disease
个性化抗性淀粉作为小儿炎症性肠病的辅助治疗
  • 批准号:
    437315
  • 财政年份:
    2020
  • 资助金额:
    $ 94.79万
  • 项目类别:
    Studentship Programs
Tailored adjuvant therapy in POLE-mutated and p53-wildtype early stage endometrial cancer (TAPER)
POLE 突变和 p53 野生型早期子宫内膜癌 (TAPER) 的定制辅助治疗
  • 批准号:
    435603
  • 财政年份:
    2020
  • 资助金额:
    $ 94.79万
  • 项目类别:
    Operating Grants
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了